ArticlemBio2021
Bacteriophage Treatment Rescues Mice Infected with Multidrug-Resistant Klebsiella pneumoniae ST258.
Open access · goldAbstract read
In one paragraph
Article in mBio, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
10.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 84 citations in OpenAlex.
- Phage anti-defense genes targeting NADVirulence · 2026Article
- Phage Therapy in Combating Multidrug-Resistant Gram-Negative Pathogens: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Efficacy and Safety Outcomes of Bacteriophage Therapy for Resistant Bacterial Infections.Cureus · 2026Review
- Efficacy of lytic bacteriophages isolated from sewage-treatment plants in Mbarara district, Uganda against ciprofloxacin-resistant Salmonella Typhi in a mice infection model.BMC infectious diseases · 2026Article
- Article
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
- Diverse Bacterial Anti-Phage Strategies: From the Laboratory to the Clinic.Current issues in molecular biology · 2026Review
- Bacteriophage Therapy AgainstMicroorganisms · 2026Review
- Effects of phage-based treatments against an OXA-48-producing Klebsiella pneumoniae isolate in simulated human gut microbiomes.BMC microbiology · 2026Article
- A conserved KL2-capsule-related phage-resistant mechanism in carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Phage and endolysin-based inhibition ofFrontiers in cellular and infection microbiology · 2026Review
- Bacterial meningitis in adults: therapeutic challenges in the era of antibiotic resistance and the potential of bacteriophages and associated by products.Frontiers in cellular and infection microbiology · 2026Review
- Characterization and Therapeutic Potential of a Novel Lytic Bacteriophage vB_Kp_H122 Targeting Multidrug-Resistant Hypervirulent Klebsiella pneumoniae of K57 Capsular Type.Transboundary and emerging diseases · 2026Article
- Phage therapy againstFrontiers in microbiology · 2026Review
- Bacteriophages as an alternative strategy for the treatment of drug resistant bacterial infections: Current approaches and future perspectives.Cell surface (Amsterdam, Netherlands) · 2025Review
- Article
- Phage and Endolysin Therapy Against Antibiotics Resistant Bacteria: From Bench to Bedside.MedComm · 2025Review
- Phage-induced protection against lethal bacterial reinfection.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Leveraging collateral sensitivity to counteract the evolution of bacteriophage resistance in bacteria.mLife · 2025Article
- Phage therapy for Klebsiella pneumoniae: Understanding bacteria-phage interactions for therapeutic innovations.PLoS pathogens · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Shayla HesseLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA shayla.hesse@nih.gov.ORCID 0000-0003-3180-1858
Natalia MalachowaLaboratory of Bacteriology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
Adeline R PorterLaboratory of Bacteriology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
Brett FreedmanLaboratory of Bacteriology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
Scott D KobayashiLaboratory of Bacteriology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
Donald J GardnerRocky Mountain Veterinary Branch, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
Dana P ScottRocky Mountain Veterinary Branch, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
Sankar AdhyaLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Frank R DeLeoLaboratory of Bacteriology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, USA.
National Institutes of Health · US
Funding
Veterinary Services Core for Infectious Diseases Research- RMLZIGAI001048 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI HANLEY, PATRICK · 2009 to 2025
$135.0MBasis for Success of Multidrug-Resistant EnterobacteriaceaeZIAAI001195 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DELEO, FRANK · 2014 to 2025
$11.9MUse of Bacteriophages to Prevent, Diagnose, and Treat DiseasesZIABC010017 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ADHYA, SANKAR · 2009 to 2025
$9.3MIntramural NIH HHS ZIA AI001195Intramural NIH HHS ZIA BC010017
Abstract
Severe infections caused by multidrug-resistant
Indexed as
Phage TherapyAnimalsAnti-Bacterial AgentsBacteremiaBacteriophagesDrug Resistance, Multiple, BacterialFemaleKlebsiella InfectionsKlebsiella pneumoniaeMiceMice, Inbred C57BLAnti-Bacterial Agentsbacteriophage therapybloodstream infectionsexperimental therapeuticsKlebsiella pneumoniaemultidrug resistance
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.